Eye Care Professional Center

An eye care professional can help to manage potential ocular adverse reactions associated with BLENREP

Ocular adverse reactions in the pooled safety population

Ocular adverse reactions occurred in 77% of 218 patients in the pooled safety population.1,a

  • Ocular adverse reactions included keratopathy (76%), changes in visual acuity (55%), blurred vision (27%), and dry eye (19%)
    • Among patients with keratopathy (n=165), 49% of patients had ocular symptoms, 65% had clinically relevant changes in visual acuity (decline of 2 or more lines on Snellen Visual Acuity in any eye), and 34% had both ocular symptoms and visual acuity changes
a
The pooled safety population reflects exposure to BLENREP at a dosage of 2.5 mg/kg or 3.4 mg/kg (1.4 times the recommended dose) administered intravenously once every 3 weeks in patients in DREAMM-2. Of these patients, 194 received a liquid formulation (not the approved dosage form) rather than the lyophilized powder.

Keratopathy1

Keratopathy of any grade per the Keratopathy and Visual Acuity (KVA) scale (N = 218)

Grade 1 Grade 2 Grade 3 Grade 4
7% 22% 45% 0.5%
  • Onset: Most keratopathy events developed within the first 2 treatment cycles (cumulative incidence of 65% by Cycle 2)
  • Recovery: 39% of the 149 patients with Grade 2-4 keratopathy recovered to Grade 1 or lower after median follow-up of 6.2 months
    • Of the 61% who had ongoing keratopathy:
      • 28% were still on treatment
      • 9% were in follow-up
      • 24% of follow-up ended due to death, study withdrawal, or being lost to follow-up
    • Median time to resolution: 2 months (range: 11 days to 8.3 months)
    • Median time to resolution: 
      • 2 months (range: 11 days to 8.3 months)
  • Cases of corneal ulcer (ulcerative and infective keratitis) have been reported

Visual acuity changes1

Changes in visual acuity may be associated with difficulty in driving or reading.

Clinically significant decreases in vision in the better-seeing eye (N = 218)

Worse than 20/40 20/200 or worse
19% 1.4%
88% resolved All patients resolved
Median time to resolution: 22 days
(range: 7 days to 4.2 months)
Median duration: 22 days
(range: 15 to 22 days)
  • No permanent loss of vision was reported in the DREAMM-2 study²
callout-brush

Patients may have been referred to an eye care professional through their hematologist’s/oncologist’s office or may seek an eye care professional directly to schedule appointments.

Find an eye care professional to support your patients being treated with BLENREP

callout-brush

Patients may have been referred to an eye care professional through their hematologist’s/oncologist’s office or may seek an eye care professional directly to schedule appointments.

Find an eye care professional to support your patients being treated with BLENREP

Find an eye care professional to support your patients being treated with BLENREP